Join the Oncology Voice Network. Join for Free
What Makes KOLs Tick
Key Opinion Leaders KOL engagement strategies proactive MSL techniques rare disease MSL roles hybrid interaction post-COVID

What Makes KOLs Tick


Share This Article


Summary

In this episode, Deanna Murray joins to delve into the intricacies of engaging with Key Opinion Leaders (KOLs). The discussion begins with understanding KOL motivations and the importance of aligning with their needs. Deanna highlights the significance of proactive strategies, effective pre-call planning, and questioning techniques. The conversation explores innovative approaches to KOL engagement, emphasizing problem-solving and tailoring presentations. The role of MSLs in rare diseases and adapting to hybrid interactions post-COVID are also covered. The episode concludes with performance enhancement tips and an acknowledgment of the sponsor, High Five Challenge.

Deanna Murray, MSL Team Lead at Sarepta Pharmaceuticals discusses what makes KOLs tick and how to be a more effective MSL

Deanna shares…

👉 How to be a more proactive MSL vs reactive

👉 What questions MSLs should be asking their KOLs

👉 Why pre-call planning is so important

👉 How to determine WHAT you should be presenting to your KOLs

👉 Creative ways to get face time with your KOLs

Click for Source
Key Opinion Leaders, KOL engagement strategies, proactive MSL techniques, rare disease MSL roles, hybrid interaction post-COVID

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Podcast
The 3 “Knows” of Effective Scientific Communication
Partner Avatar MSL Talk: Tom Caravela, Linda Taylor

The 3 “Knows” of Effective Scientific Communication

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN